Stifel lowered the firm’s price target on Astrana Health (ASTH) to $56 from $70 and keeps a Buy rating on the shares ahead of Astrana reporting Q4 earnings on Thursday, February 27. The firm expects the call to be focused on integration of CHS and close of Prospect Health, 2025 guidance and medical cost trends, and progress in transitioning to full-risk, the analyst tells investors in a preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: